Targeted Molecules Acquired by Chromos

San Diego-based biopharmaceuticals firm Targeted Molecules has been acquired by Chromos, a Canadian biotceh firm. Targeted Molecules is developing two antibody products for the treatment of multiple sclerosis and acute thrombosis. Targeted Molecules is backed by GeneChem, FAT Capital, GC&H Investments, Inglewood Ventures, Linkagene, Neuro Discovery, and Trian Equities and most recently received a round of funding in 2003.